Ömer Faruk Şahin
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Ömer Faruk Şahin has a total of 25 co-authors. Here are the top co-authors by number of shared publications:
- Tevfik Fikret Çermik
University of Health Sciences Türkiye, İstanbul Training and Research Hospital, Clinic of Nuclear Medicine, İstanbul, Türkiye
5 shared publications - Esra Arslan
Department of Nuclear Medicine, University of Health Sciences Turkey, Istanbul Training and Research Hospital, 34098 Istanbul, Turkey
4 shared publications - Nurhan Ergül
Univ Hlth Sci Turkiye, Istanbul Training & Res Hosp, Clin Nucl Med, Istanbul, Turkiye
3 shared publications - Rahime Şahin
Clinic of Nuclear Medicine
3 shared publications - Zehranur Tosunoğlu
University of Health Sciences Türkiye, İstanbul Training and Research Hospital, Clinic of Nuclear Medicine, İstanbul, Türkiye
3 shared publications - Dilruba Şahin
Department of Nuclear Medicine, Istanbul Medeniyet University, Göztepe Prof. Dr. Süleyman Yalçin City Hospital, Istanbul, Turkey
2 shared publications
Latest Publications
- Open Access
- 30 July 2026
- Published by Mersin University in Molecular Oncologic Imaging
- Vol. 6 (2)
Isolated Primary B-Cell Lymphoma of the Larynx Mimicking Carcinoma: 18F-FDG PET/CT Findings
Primary laryngeal lymphoma is an extremely rare extranodal manifestation of non-Hodgkin lymphoma, accounting for less than 1% of all laryngeal neoplasms. We report a case of isolated primary B-cell lymphoma of the larynx evaluated with 18F-FDG PET/CT imaging. PET/CT demonstrated intense FDG uptake (SUVmax: 16.3) in the laryngeal lesion, while mild FDG uptake (SUVmax: 5.5) was observed in the right palatine tonsil, likely of inflammatory origin. The patient underwent R-CHOP therapy, and both interim and post-treatment PET/CT scans showed complete metabolic and anatomic response. This case highlights the critical role of 18F-FDG PET/CT in the staging and management of rare primary laryngeal lymphomas.
- 30 July 2026
- Published by Mersin University in Molecular Oncologic Imaging
- Vol. 6 (2)
Open AccessIsolated Primary B-Cell Lymphoma of the Larynx Mimicking Carcinoma: 18F-FDG PET/CT Findings
Primary laryngeal lymphoma is an extremely rare extranodal manifestation of non-Hodgkin lymphoma, accounting for less than 1% of all laryngeal neoplasms. We report a case of isolated primary B-cell lymphoma of the larynx evaluated with 18F-FDG PET/CT imaging. PET/CT demonstrated intense FDG uptake (SUVmax: 16.3) in the laryngeal lesion, while mild FDG uptake (SUVmax: 5.5) was observed in the right palatine tonsil, likely of inflammatory origin. The patient underwent R-CHOP therapy, and both interim and post-treatment PET/CT scans showed complete metabolic and anatomic response. This case highlights the critical role of 18F-FDG PET/CT in the staging and management of rare primary laryngeal lymphomas.
- 18 June 2026
- Published by Wolters Kluwer Health in Clinical Nuclear Medicine
- Vol. 51 (9) , e759-e767
Clinical Value of 68Ga-DOTA-Bombesin PET/CT Compared With 18F-FDG PET/CT in the Staging of Breast Cancer
Aim: To prospectively evaluate the diagnostic performance of 68 Ga-DOTA-Bombesin PET/CT compared with 18 F-FDG PET/CT in breast cancer (BC), emphasizing its utility across molecular subtypes and nodal staging. Patients and Methods: Twenty-four patients with biopsy-proven BC who underwent both 68 Ga-DOTA-Bombesin and 18 F-FDG PET/CT were included. Imaging findings were analyzed on a per-lesion and per-patient basis for primary tumor detection, axillary lymph-node involvement, and distant metastases. Quantitative parameters (SUVmax, MTV, and tumor-to-background ratios) were compared across histopathologic and receptor subgroups, with histopathology as the reference standard. Results: 68 Ga-DOTA-Bombesin visualized 92.3% of primary tumors, achieving comparable sensitivity to 18 F-FDG (84.6%) but higher specificity in nodal staging (100% vs. 53.8%). Bombesin uptake correlated strongly with estrogen receptor positivity and a lower Ki-67 index ( P 68 Ga-DOTA-Bombesin PET/CT provides a receptor-specific imaging approach in BC, showing complementary strengths to 18 F-FDG, particularly in hormone-receptor–positive and low-proliferation tumors. Its superior nodal specificity and theranostic potential support further evaluation of GRPR-targeted imaging and therapy in personalized BC management.
- 18 June 2026
- Published by Wolters Kluwer Health in Clinical Nuclear Medicine
- Vol. 51 (9) , e759-e767
Clinical Value of 68Ga-DOTA-Bombesin PET/CT Compared With 18F-FDG PET/CT in the Staging of Breast Cancer
Aim: To prospectively evaluate the diagnostic performance of 68 Ga-DOTA-Bombesin PET/CT compared with 18 F-FDG PET/CT in breast cancer (BC), emphasizing its utility across molecular subtypes and nodal staging. Patients and Methods: Twenty-four patients with biopsy-proven BC who underwent both 68 Ga-DOTA-Bombesin and 18 F-FDG PET/CT were included. Imaging findings were analyzed on a per-lesion and per-patient basis for primary tumor detection, axillary lymph-node involvement, and distant metastases. Quantitative parameters (SUVmax, MTV, and tumor-to-background ratios) were compared across histopathologic and receptor subgroups, with histopathology as the reference standard. Results: 68 Ga-DOTA-Bombesin visualized 92.3% of primary tumors, achieving comparable sensitivity to 18 F-FDG (84.6%) but higher specificity in nodal staging (100% vs. 53.8%). Bombesin uptake correlated strongly with estrogen receptor positivity and a lower Ki-67 index ( P 68 Ga-DOTA-Bombesin PET/CT provides a receptor-specific imaging approach in BC, showing complementary strengths to 18 F-FDG, particularly in hormone-receptor–positive and low-proliferation tumors. Its superior nodal specificity and theranostic potential support further evaluation of GRPR-targeted imaging and therapy in personalized BC management.
- 3 April 2026
- Published by Wolters Kluwer Health in Clinical Nuclear Medicine
- Vol. 51 (9) , e818-e819
The Sunburst Sign in the Mesentery: Unveiling the Diagnosis With ⁶⁸Ga DOTATATE PET/CT
Contrast-enhanced abdominal CT of a 57-year-old man presenting with abdominal pain and diarrhea revealed a spiculated, calcified mesenteric mass, initially suggesting a desmoid tumor (DT). The lesion’s ametabolic nature on 18 F-FDG PET/CT supported this suspicion. However, ⁶⁸Ga DOTATATE PET/CT demonstrated intense uptake in both the mesenteric mass, which exhibited a “sunburst” calcification pattern, and the primary ileal focus. Histopathology confirmed an ileal neuroendocrine tumor (NET) with mesenteric lymph node metastasis. This case highlights the critical role of ⁶⁸Ga DOTATATE PET/CT in the differential diagnosis, primary site detection, and accurate staging of FDG-negative mesenteric masses associated with a desmoplastic reaction.
- 3 April 2026
- Published by Wolters Kluwer Health in Clinical Nuclear Medicine
- Vol. 51 (9) , e818-e819
The Sunburst Sign in the Mesentery: Unveiling the Diagnosis With ⁶⁸Ga DOTATATE PET/CT
Contrast-enhanced abdominal CT of a 57-year-old man presenting with abdominal pain and diarrhea revealed a spiculated, calcified mesenteric mass, initially suggesting a desmoid tumor (DT). The lesion’s ametabolic nature on 18 F-FDG PET/CT supported this suspicion. However, ⁶⁸Ga DOTATATE PET/CT demonstrated intense uptake in both the mesenteric mass, which exhibited a “sunburst” calcification pattern, and the primary ileal focus. Histopathology confirmed an ileal neuroendocrine tumor (NET) with mesenteric lymph node metastasis. This case highlights the critical role of ⁶⁸Ga DOTATATE PET/CT in the differential diagnosis, primary site detection, and accurate staging of FDG-negative mesenteric masses associated with a desmoplastic reaction.
- 24 March 2026
- Published by Wolters Kluwer Health in Clinical Nuclear Medicine
- Vol. 51 (7) , e422-e430
Diagnostic Performance of 68Ga DOTA-Pentixafor PET/CT in Benign Functional Adrenal Cortical Lesions
Objective: This prospective study evaluated the diagnostic performance of 68 Ga DOTA-Pentixafor PET/CT in characterizing the functional properties and lateralization of aldosterone-producing and cortisol-producing adrenal cortical lesions. The contribution of Pentixafor PET/CT to diagnosis and treatment planning was assessed in comparison with CT, MRI, and 18 F-FDG PET/CT. Patients and Methods: Twenty-five patients with suspected benign functional adrenal cortical masses were included. All patients underwent whole-body imaging at 1 hour and delayed abdominal imaging at 2 hours following intravenous administration of 18 F-FDG and 68 Ga DOTA-Pentixafor. Lesion SUVmax, LCRSUVmax, and LLRSUVmax values were analyzed and correlated with laboratory parameters, other imaging modalities, and postoperative clinical and pathologic outcomes. Results: 68 Ga DOTA-Pentixafor PET/CT demonstrated distinct focal uptake relative to the contralateral adrenal gland and liver parenchyma in 6/6 (100%) patients with suspected PA, 5/18 (27.7%) with suspected CS, and 1/1 (100%) with suspected EAS. Among patients with focal uptake who underwent surgery, all PA (5/5) and all CS (5/5) cases were confirmed as adrenocortical adenomas, resulting in no false-positive findings (PPV 100%). However, due to 2 false-negative CS cases, pentixafor PET/CT demonstrated an overall sensitivity of 83.3%, specificity of 100%, and accuracy of 85.7%. Thresholds of SUVmax >15.11, LCRSUVmax >1.74, and LLRSUVmax >4.36 yielded sensitivities of 33.3%, 41.7%, and 41.7%, respectively, while maintaining 100% specificity. Clinical and biochemical improvement was observed in 100% (5/5) of operated PA patients and 100% (5/5) of operated CS patients. Follow-up of nonoperated patients is ongoing. Conclusion: 68 Ga DOTA-Pentixafor PET/CT is a valuable diagnostic and potentially therapeutic tool for benign functional adrenal cortical disorders such as PA, CS, and EAS, with the potential to establish a new standard in minimally invasive patient management.
- 24 March 2026
- Published by Wolters Kluwer Health in Clinical Nuclear Medicine
- Vol. 51 (7) , e422-e430
Diagnostic Performance of 68Ga DOTA-Pentixafor PET/CT in Benign Functional Adrenal Cortical Lesions
Objective: This prospective study evaluated the diagnostic performance of 68 Ga DOTA-Pentixafor PET/CT in characterizing the functional properties and lateralization of aldosterone-producing and cortisol-producing adrenal cortical lesions. The contribution of Pentixafor PET/CT to diagnosis and treatment planning was assessed in comparison with CT, MRI, and 18 F-FDG PET/CT. Patients and Methods: Twenty-five patients with suspected benign functional adrenal cortical masses were included. All patients underwent whole-body imaging at 1 hour and delayed abdominal imaging at 2 hours following intravenous administration of 18 F-FDG and 68 Ga DOTA-Pentixafor. Lesion SUVmax, LCRSUVmax, and LLRSUVmax values were analyzed and correlated with laboratory parameters, other imaging modalities, and postoperative clinical and pathologic outcomes. Results: 68 Ga DOTA-Pentixafor PET/CT demonstrated distinct focal uptake relative to the contralateral adrenal gland and liver parenchyma in 6/6 (100%) patients with suspected PA, 5/18 (27.7%) with suspected CS, and 1/1 (100%) with suspected EAS. Among patients with focal uptake who underwent surgery, all PA (5/5) and all CS (5/5) cases were confirmed as adrenocortical adenomas, resulting in no false-positive findings (PPV 100%). However, due to 2 false-negative CS cases, pentixafor PET/CT demonstrated an overall sensitivity of 83.3%, specificity of 100%, and accuracy of 85.7%. Thresholds of SUVmax >15.11, LCRSUVmax >1.74, and LLRSUVmax >4.36 yielded sensitivities of 33.3%, 41.7%, and 41.7%, respectively, while maintaining 100% specificity. Clinical and biochemical improvement was observed in 100% (5/5) of operated PA patients and 100% (5/5) of operated CS patients. Follow-up of nonoperated patients is ongoing. Conclusion: 68 Ga DOTA-Pentixafor PET/CT is a valuable diagnostic and potentially therapeutic tool for benign functional adrenal cortical disorders such as PA, CS, and EAS, with the potential to establish a new standard in minimally invasive patient management.
- 7 February 2026
- Published by Elsevier in Journal of Nuclear Cardiology
- Vol. 63, 102654
Physiological differences in bone uptake of [99mTc]Tc-pyrophosphate in men and women undergoing cardiac scintigraphy
- 7 February 2026
- Published by Elsevier in Journal of Nuclear Cardiology
- Vol. 63, 102654
Physiological differences in bone uptake of [99mTc]Tc-pyrophosphate in men and women undergoing cardiac scintigraphy
- Open Access
- 1 June 2023
- Published by Galenos Yayinevi in Molecular Imaging and Radionuclide Therapy
- Vol. 32 (2) , 153-155
Cutaneous Metastase of Rectal Neuroendocrine Carcinoma Revealed on 18F-FDG PET/CT
Rectal neuroendocrine carcinomas constitute 18F-fluorodeoxyglucose (FDG) positron emission tomography/computed tomography for restaging after 6 cycles of chemotherapy and radiotherapy. Intensely increased 18F-FDG uptake in the right cutaneous inguinal region was consistent with neuroendocrine carcinoma metastasis with biopsy from the same region.
- 1 June 2023
- Published by Galenos Yayinevi in Molecular Imaging and Radionuclide Therapy
- Vol. 32 (2) , 153-155
Open AccessCutaneous Metastase of Rectal Neuroendocrine Carcinoma Revealed on 18F-FDG PET/CT
Rectal neuroendocrine carcinomas constitute 18F-fluorodeoxyglucose (FDG) positron emission tomography/computed tomography for restaging after 6 cycles of chemotherapy and radiotherapy. Intensely increased 18F-FDG uptake in the right cutaneous inguinal region was consistent with neuroendocrine carcinoma metastasis with biopsy from the same region.
- Open Access
- 1 June 2023
- Published by Galenos Yayinevi in Molecular Imaging and Radionuclide Therapy
- Vol. 32 (2) , 156-158
Testicular Metastasis of Jejunal Neuroendocrine Tumor on 68Ga-DOTATATE PET/CT
Neuroendocrine tumors are slow-growing tumors originating from neuroendocrine cells and capable of metastasis. Most of them are found in the gastrointestinal tract; however, they can also be rarely seen in other organs. Testicular neuroendocrine tumors account for less than 1% of all testicular neoplasms. They may present as primary testicular or secondary tumors from extratesticular sources. Jejunal neuroendocrine tumor metastasis to the testis is extremely rare. We present the case of a 61-year-old man with a jejunal neuroendocrine tumor and metastases to bilateral testicles revealed on Gallium-68-DOTATATE positron emission tomography/computed tomography.
- 1 June 2023
- Published by Galenos Yayinevi in Molecular Imaging and Radionuclide Therapy
- Vol. 32 (2) , 156-158
Open AccessTesticular Metastasis of Jejunal Neuroendocrine Tumor on 68Ga-DOTATATE PET/CT
Neuroendocrine tumors are slow-growing tumors originating from neuroendocrine cells and capable of metastasis. Most of them are found in the gastrointestinal tract; however, they can also be rarely seen in other organs. Testicular neuroendocrine tumors account for less than 1% of all testicular neoplasms. They may present as primary testicular or secondary tumors from extratesticular sources. Jejunal neuroendocrine tumor metastasis to the testis is extremely rare. We present the case of a 61-year-old man with a jejunal neuroendocrine tumor and metastases to bilateral testicles revealed on Gallium-68-DOTATATE positron emission tomography/computed tomography.
- Open Access
- 19 October 2022
- Published by Galenos Yayinevi in Molecular Imaging and Radionuclide Therapy
- Vol. 31 (3) , 200-206
Prognostic Significance of 18F-FDG PET/CT Imaging in Survival Outcomes in Patients with Renal Cell Carcinoma
Renal cell carcinoma (RCC) comprises 85%-90% of primary renal malignant tumors originating from the renal tubular epithelium and has different genetic characteristics. This study aimed to investigate the potential predictive role of 18F-fluorodeoxyglucose (FDG) positron emission tomography/computed tomography (PET/CT) and metabolic parameters in overall survival (OS) analysis in patients with RCC. 18F-FDG PET/CT images of 100 patients performed for initial staging before surgical or oncological treatments were analyzed retrospectively. Maximum standard uptake value (SUVmax-T) of the primary tumor was calculated and its relationship to patient survival was analyzed. The median follow-up time was 5.61 years (0.01-8.7 years). SUVmax-T levels in the patients ranged from 2.1 to 48.9 (median 5.9, mean 9.0±7.9). SUVmax-T was significantly higher in RCC-related death more positive than in the negative cases (pmax-T for estimating OS was a cut-off level of 5.4, which maintained sensitivity and specificity of 81% and 75%, respectively. However, cancer staging remained independent significance for OS (pmax of primary tumor and cancer stage were demonstrated as significant prognostic factors for OS in patients with RCC. Evaluation of 18F-FDG accumulation with PET/CT may help plan treatment strategies and predict survival outcomes of these patients at diagnosis.
- 19 October 2022
- Published by Galenos Yayinevi in Molecular Imaging and Radionuclide Therapy
- Vol. 31 (3) , 200-206
Open AccessPrognostic Significance of 18F-FDG PET/CT Imaging in Survival Outcomes in Patients with Renal Cell Carcinoma
Renal cell carcinoma (RCC) comprises 85%-90% of primary renal malignant tumors originating from the renal tubular epithelium and has different genetic characteristics. This study aimed to investigate the potential predictive role of 18F-fluorodeoxyglucose (FDG) positron emission tomography/computed tomography (PET/CT) and metabolic parameters in overall survival (OS) analysis in patients with RCC. 18F-FDG PET/CT images of 100 patients performed for initial staging before surgical or oncological treatments were analyzed retrospectively. Maximum standard uptake value (SUVmax-T) of the primary tumor was calculated and its relationship to patient survival was analyzed. The median follow-up time was 5.61 years (0.01-8.7 years). SUVmax-T levels in the patients ranged from 2.1 to 48.9 (median 5.9, mean 9.0±7.9). SUVmax-T was significantly higher in RCC-related death more positive than in the negative cases (pmax-T for estimating OS was a cut-off level of 5.4, which maintained sensitivity and specificity of 81% and 75%, respectively. However, cancer staging remained independent significance for OS (pmax of primary tumor and cancer stage were demonstrated as significant prognostic factors for OS in patients with RCC. Evaluation of 18F-FDG accumulation with PET/CT may help plan treatment strategies and predict survival outcomes of these patients at diagnosis.